Carola Wagner
8 IP cases indexed. Covers patent matters.
Cases Presided Over
8 cases indexed | Page 1 of 1
Sanofi SA as successor of Sanofi Mature IP v.STADAPHARM GmbH a.o.
In a significant ruling, the UPC Local Division Munich revoked European Patent 2 493 466 in its entirety. The patent, which covered a novel anti-tumoral use of cabazitaxel (marketed as JEVTANA), was found invalid across several key member states. Consequently, all associated infringement actions brought by Sanofi against generic manufacturers like STADAPHARM were dismissed. This case highlights the vulnerability of patents facing prior national challenges and underscores the UPC's role in enforcing or nullifying IP rights.
Sanofi SA as successor of Sanofi Mature IP a.o. v.Reddy Pharma SAS
In a significant pharmaceutical case, the UPC Local Division Munich revoked European Patent 2 493 466, which covered a novel anti-tumoral use of cabazitaxel. The revocation was based on prior findings of invalidity concerning the patent's scope and obviousness. Consequently, all associated infringement claims brought by Sanofi against generic manufacturers like Reddy Pharma were dismissed. This decision underscores the powerful impact of national invalidation proceedings on UPC rights.
Sanofi SA as successor of Sanofi Mature IP v.Zentiva France
In a significant pharmaceutical case, the UPC Local Division Munich revoked European Patent 2 493 466 concerning the anti-tumoral use of cabazitaxel. The revocation was based on prior invalidation proceedings in France, which demonstrated how national court decisions can directly impact patent validity within the unified system. Consequently, all associated infringement actions brought by Sanofi against generic manufacturers like Zentiva were dismissed.
Sanofi SA as successor of Sanofi Mature IP a.o. v.Reddy Pharma SAS
In a significant ruling concerning pharmaceutical patents, the UPC Local Division Munich revoked European Patent 2 493 466. This patent covered a novel anti-tumoral use of cabazitaxel, which was marketed under the brand name JEVTANA by Sanofi. The revocation decision immediately dismissed all associated infringement actions brought by Sanofi against generic competitors like Reddy Pharma SAS. This case underscores the powerful effect of successful revocation proceedings within the UPC framework.
Sanofi SA as successor of Sanofi Mature IP v.Zentiva France
In a significant pharmaceutical case, the UPC Local Division Munich revoked European Patent 2 493 466 concerning the anti-tumoral use of cabazitaxel. The revocation decision effectively dismissed the concurrent infringement actions brought by Sanofi against generic manufacturers like Zentiva. This ruling underscores the power of the UPC to enforce patent validity across multiple jurisdictions, even when national court decisions regarding invalidity are involved.
Sanofi SA as successor of Sanofi Mature IP v.STADAPHARM GmbH a.o.
In a significant ruling for the pharmaceutical sector, the UPC Local Division Munich revoked European Patent 2 493 466, which covered a novel anti-tumoral use of cabazitaxel. This decision immediately dismissed the associated infringement actions brought by Sanofi against generic competitors such as Stada and Dr Reddy's. The ruling underscores the vulnerability of patents, even those related to specific medical uses, when challenged successfully on grounds of invalidity.
Boehringer Ingelheim International GmbH v.Zentiva Portugal, LDA.
In a significant decision regarding generic drug competition, the UPC Court of Appeal granted provisional measures in favor of Boehringer Ingelheim against Zentiva. The court held that the completion of national health technology assessments and reimbursement procedures for generics can constitute an imminent infringement threat, even before market launch. This ruling reinforces the proactive nature of the UPC's jurisdiction across all member states, providing a strong deterrent against premature generic entry.
Sanofi (various entities) v.Medac Gesellschaft für klinische Spezialpräparate m.b.H.
This procedural order addressed Medac's attempt to withdraw an application concerning a privileged and confidential document (Exhibit 2) that had been uploaded into the UPC system. The court permitted the withdrawal but issued a strong warning against Medac's representative for negligently breaching the Code of Conduct by uploading the unredacted material. This decision underscores the strict procedural requirements regarding confidentiality and evidence handling within the UPC framework.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.